| Assessment Status | Rapid Review Complete |
| HTA ID | 25057 |
| Drug | Teprotumumab |
| Brand | Tepezza® |
| Indication | Teprotumumab (Tepezza®) is indicated in adults for the treatment of moderate to severe thyroid eye disease. |
| Assessment Process | |
| Rapid review commissioned | 16/09/2025 |
| Rapid review completed | 15/10/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teprotumumab compared with the current standard of care. |